Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing parathyroid disorders
3.2.1.2 Increasing government initiatives
3.2.1.3 Rising technological advancements
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.2.2.2 Associated side effects
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.5.1 Supplier power
3.5.2 Buyer power
3.5.3 Threat of new entrants
3.5.4 Threat of substitutes
3.5.5 Industry rivalry
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive positioning matrix
4.4 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Product Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Supplements
5.2.1 Calcium supplements
5.2.2 Vitamin D supplements
5.2.3 Other supplements
5.2.3.1 Magnesium
5.2.3.2 Zinc
5.3 Parathyroid hormone
Chapter 6 Market Estimates and Forecast,By Route of Administration 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Oral
6.3 Parenteral
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacy
7.3 Retail pharmacy
7.4 Online pharmacy
Chapter 8 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 South Africa
8.6.3 Rest of Middle East & Africa
Chapter 9 Company Profiles
9.1 Ascendis Pharma A/S
9.2 Amgen Inc.
9.3 BioNTech SE
9.4 Bristol-Myers Squibb Company
9.5 Entera Bio Ltd.
9.6 F. Hoffmann-La Roche Ltd.
9.7 Merck & Co., Inc.
9.8 SK biopharmaceuticals Co., Ltd.
9.9 Sun Pharmaceutical Industries Ltd.
9.10 Takeda Pharmaceutical Company Limited.
